PRESS RELEASES
Page 1 of 28
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
02/04/2021
Onxeo publishes Letter to Shareholders and provides update on its developments
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
02/02/2021
Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
01/28/2021
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
01/11/2021
2020 – Full-year report on the liquidity contract
2020 Full-year report on the liquidity contract
01/08/2021
Onxeo Announces its Financial Agenda for 2021
Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
01/07/2021
Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020
Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]
12/10/2020
Onxeo has received approval for the delisting from Nasdaq Main Market Copenhagen and the concurrent admission to trading on Nasdaq First North Growth Market Denmark
Last day of trading on Nasdaq Copenhagen will be 11 December 2020 and the first day of trading on Nasdaq […]
11/30/2020
Page 1 of 28